Equibles does not estimate personal net worth.
Get an email with a short summary when Regeneron Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get REGN alertsThe proxy statement of Regeneron Pharmaceuticals, Inc. reports total compensation of $6,796,783 for George Yancopoulos in fiscal 2024, including a base salary of $1,941,100. Disclosed compensation is on record for 8 fiscal years. George Yancopoulos has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Regeneron Pharmaceuticals, Inc. on October 30, 2026. Regeneron Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Regeneron Pharmaceuticals, Inc. includes George D. Yancopoulos, M.D., Ph.D. (Chairman), Leonard S. Schleifer, M.D., Ph.D. (Chairman), Joseph J. LaRosa (General Counsel) and 7 others.
“For my remarks today, I'll first provide further details on the four programs that Len highlighted, then cover other key updates from our pipeline. Beginning with our C5 program, regulatory submissions are under review for Cendisarine, our C5 sRNA, for generalized Mycenae gravis, or GMG.”
“Before I discuss the new antibodies being added to the alliance, I'd like to briefly reflect on the incredible dupexin development journey that Regeneron and Sanofi have jointly shared over the past decade plus.”
“Earlier this month at the JPMorgan Conference, we highlighted the breadth and depth of our pipeline, which is expected to generate clinical data over the next few years, spanning oncology, hematology, complement-mediating diseases, anticoagulation, and obesity, as well as in other areas.”
“Over the last few months, as Len just mentioned, we have delivered multiple important data readouts, showcasing the strength of our robust pipeline and the potential to drive future growth with positive pivotal data for Dupixent for our C5 program, our cat and birch allergy programs, as well as in our rare disease…”
“That was a really impressive overview I have to say. 2023 was another year of firsts delivered by Regeneron as well as together with our collaborators, all of which have the potential to change the practice of medicine.”
Source not stated
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,941,100 | $6,796,783 |
| 2023 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,875,415 | $7,759,830 |
| 2022 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,811,995 | $6,593,696 |
| 2021 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer | $1,767,800 | $6,398,364 |
| 2020 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,258,096 | $134,383,319 |
| 2019 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,170,500 | $20,664,135 |
| 2018 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,130,900 | $25,381,129 |
| 2017 | Regeneron Pharmaceuticals, Inc. (REGN) | M.D., Ph.D. President and Chief Scientific Officer | $1,092,700 | $25,299,239 |
